Home > > > > > Report Detail

Global Autoimmune Partnering 2012-2018: Deal trends, players and financials

Publisher Name :
Date: 01-Oct-2018
No. of pages: 700
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

The Global Autoimmune Partnering 2012-2018: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the autoimmune disease partnering deals and agreements entered into by the worlds leading healthcare companies

Global Autoimmune Partnering 2012 to 2018 provides the full collection of Autoimmune disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.

Trends in Autoimmune partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Autoimmune partnering agreement structure

Autoimmune partnering contract documents

Top Autoimmune deals by value

Most active Autoimmune dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Autoimmune disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Autoimmune deals.

The report includes coverage of the following autoimmune diseases:

Multiple sclerosis, Restless leg syndrome, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison's disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.

The report presents financial deal terms values for Autoimmune deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Autoimmune dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Autoimmune dealmaking since 2012 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Autoimmune deals since 2012. Deals are listed by headline value. The chapter includes the top 25 most active Autoimmune dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Autoimmune deals since 2012 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Autoimmune partnering deals by specific Autoimmune target announced since 2012. The chapter is organized by specific Autoimmune therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Autoimmune partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Autoimmune partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Autoimmune technologies and products.

Benefits

Global Autoimmune Partnering 2012 to 2018 provides the reader with the following key benefits:

In-depth understanding of Autoimmune deal trends since 2012

Access Autoimmune deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Autoimmune partner companies

Comprehensive access to over 500 links to actual Autoimmune deals entered into by the world's biopharma companies

Indepth review of Autoimmune deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Autoimmune opportunities

Uncover companies actively partnering Autoimmune opportunities

Global Autoimmune Partnering 2012-2018: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Autoimmune dealmaking
2.1. Introduction
2.2. Autoimmune partnering over the years
2.3. Autoimmune partnering by deal type
2.4. Autoimmune partnering by industry sector
2.5. Autoimmune partnering by stage of development
2.6. Autoimmune partnering by technology type
2.7. Autoimmune partnering by therapeutic indication

Chapter 3 -Financial deal terms for Autoimmune partnering
3.1. Introduction
3.2. Disclosed financials terms for Autoimmune partnering
3.3. Autoimmune partnering headline values
3.4. Autoimmune deal upfront payments
3.5. Autoimmune deal milestone payments
3.6. Autoimmune royalty rates

Chapter 4 - Leading Autoimmune deals and dealmakers
4.1. Introduction
4.2. Most active in Autoimmune partnering
4.3. List of most active dealmakers in Autoimmune
4.4. Top Autoimmune deals by value

Chapter 5 - Autoimmune contract document directory
5.1. Introduction
5.2. Autoimmune partnering deals where contract document available

Chapter 6 - Autoimmune dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Autoimmune therapeutic target

Appendices
Appendix 1 - Directory of Autoimmune deals by company A-Z 2012 to 2018
Appendix 2 - Directory of Autoimmune deals by deal type 2012 to 2018
Appendix 3 - Directory of Autoimmune deals by stage of development 2012 to 2018
Appendix 4 - Directory of Autoimmune deals by technology type 2012 to 2018
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Tables and Figures

Figure 1: Autoimmune partnering since 2012
Figure 2: Autoimmune partnering by deal type since 2012
Figure 3: Autoimmune partnering by industry sector since 2012
Figure 4: Autoimmune partnering by stage of development since 2012
Figure 5: Autoimmune partnering by technology type since 2012
Figure 6: Autoimmune partnering by indication since 2012
Figure 7: Autoimmune deals with a headline value
Figure 8: Autoimmune deals with upfront payment values
Figure 9: Autoimmune deals with milestone payment
Figure 10: Autoimmune deals with royalty rates
Figure 11: Active Autoimmune dealmaking activity- 2012 to 2018
Figure 12: Top Autoimmune deals by value since 2012
  • Global Systemic Lupus Erythematosus (Sle) Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 28-Nov-2023        Price: US 3380 Onwards        Pages: 109
    Market Overview of Global Systemic Lupus Erythematosus (Sle) Drugs market: According to our latest research, the global Systemic Lupus Erythematosus (Sle) Drugs market looks promising in the next 5 years. As of 2022, the global Systemic Lupus Erythematosus (Sle) Drugs market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents......
  • Autoimmune Drugs Industry Forecasts - China Focus
    Published: 27-Nov-2023        Price: US 1800 Onwards        Pages: 78
    This study focuses on China's Autoimmune Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services. Th......
  • Autoimmune Drugs Companies in China
    Published: 27-Nov-2023        Price: US 1800 Onwards        Pages: 71
    This study focuses on China's Autoimmune Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of......
  • Autoimmune Drugs Markets in China
    Published: 27-Nov-2023        Price: US 4000 Onwards        Pages: 201
    China's demand for Autoimmune Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, indu......
  • Autoimmune Collaboration and Licensing Deals 2016-2023
    Published: 01-Oct-2023        Price: US 3995 Onwards        Pages: 450
    Autoimmune Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the autoimmune deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of autoimmune deals from 2016 to 2023. The report includes coverage of the following autoimmune diseases: Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Infla......
  • Global Autoimmune Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 29-Aug-2023        Price: US 3380 Onwards        Pages: 101
    Market Overview of Global Autoimmune Drugs market: According to our latest research, the global Autoimmune Drugs market looks promising in the next 5 years. As of 2022, the global Autoimmune Drugs market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Autoimmune Drugs market......
  • Global Autoimmune Drugs Market Insights, Forecast to 2029
    Published: 14-Aug-2023        Price: US 4900 Onwards        Pages: 92
    Abnormal immune responses of the innate immune system can cause autoimmune diseases, which can damage body tissues and lead to abnormal organ functions. Immunological complications due to physiological processes within the human body lead to autoimmune diseases. These diseases are characterized by chronic inflammatory processes that activate the innate immune system and the production of antibodies that destroy host tissues. These inflammatory processes can be caused by genetic or environmental ......
  • Global Systemic Lupus Erythematosus (SLE) Drugs Market Insights, Forecast to 2029
    Published: 14-Aug-2023        Price: US 4900 Onwards        Pages: 75
    SLE is the most common form of lupus and is also called lupus. It is a chronic, autoimmune disease with signs and symptoms that can last for six months or for many years. It can affect any part of the body, such as the skin, joints, and organs (LFA, 2012). SLE occurs when the immune system produces autoantibodies, which attack and destroy healthy tissues in the body rather than foreign infectious agents. These autoantibodies cause inflammation, pain, and damage. It is also known as a disease of ......
  • Global Systemic Lupus Erythematosus (Sle) Drugs Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 11-Jul-2023        Price: US 3260 Onwards        Pages: 130
    The Systemic Lupus Erythematosus (Sle) Drugs market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Systemic Lupus Erythematosus (Sle) Drugs industry, and breaks down according to the type, application, and consumption area of Systemic Lupus Erythematosus (Sle) Drugs. The report also introduces players in the industry from the per......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs